Autobahn plans to evaluate ABX-002 in major depressive disorder patients in a prospective Phase II trial. Credit: kan_chana / Shutterstock.com.

Autobahn Therapeutics has reported positive topline data from a Phase I clinical trial of ABX-002 in healthy subjects to potentially treat major depressive disorder (MDD).

The double-blind, randomised, placebo-controlled trial evaluated the tolerability, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral, once-a-day, escalating doses of ABX-002.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

It enrolled a total of 48 subjects in the single ascending dose (SAD) and multiple ascending dose (MAD) portions of the trial.

According to the trial data, various tested doses of ABX-002 were found to be safe and well-tolerated.

No serious adverse events were reported, with ABX-002 showing satisfactory dose-relative PK across both portions of the study.

A top dose of the therapy showed brain target engagement (mood alteration) observed in the MAD section, which is in line with brain-activating thyroid effects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile ā€“ free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Based on this data, the company plans to file an investigational new drug (IND) application with the US Food and Drug Administration to launch a Phase II trial of ABX-002 in the first half of next year.

Autobahn will evaluate ABX-002 as an adjunctive therapy for MDD patients in the Phase II trial.

A selective thyroid hormone beta receptor (TRĪ²) agonist, ABX-002 has shown target engagement in regions of the brain linked with depression.

Autobahn Therapeutics research and development head and executive vice-president Gudarz Davar said: ā€œWe are encouraged by this Phase I study results, which demonstrate CNS target engagement and an overall favourable PK, safety, and tolerability profile for ABX-002.Ā 

ā€œSynthetic thyroid hormone treatment is well understood to offer benefit as an adjunctive treatment for MDD, however, it is not approved for use in the US and its clinical utility is limited largely due to concerns about long-term safety and monitoring.ā€